KRAS and neoplasm: In the 10 studies that reported objective tumor response to cetuximab-containing therapy, the median RR in patients with KRAS WT tumors was 35% (range 12% – 42%) compared with 0% (range 0% – 6%) in patients with KRAS MT tumors.